Skip to main content
Journal ArticleOPEN ACCESS

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma

  • Xiaorong L
  • Wei W
  • Liyuan Q
  • et al.
BMC Cancer (2008) 8(1)
DOI: 10.1186/1471-2407-8-205
N/ACitations
Citations of this article
2Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

DLC2, a unique RhoGAP, has been recently identified as a tumor suppressor gene in hepatocellular carcinoma (HCC). However, the expression of DLC2 protein, and its relationship with RhoA in clinical hepatocellular carcinoma have not been studied. The aim of this study was to investigate the DLC2 protein expression and its correlation with expression of RhoA, as well as to evaluate the prognostic value of DLC2 for HCC patients.

Cite

CITATION STYLE

APA

Xiaorong, L., Wei, W., Liyuan, Q., & Kaiyan, Y. (2008). Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma. BMC Cancer, 8(1). https://doi.org/10.1186/1471-2407-8-205

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free